After a year of hesitation in the face of pending cost control guidelines, Vertex Pharmaceuticals has submitted Trikafta to Health Canada for approval – now the hard work begins, writes Jeremie Saunders.

This entry was posted on Wednesday, November 18th, 2020 at 7:10 am and is filed under Finance/ Money. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.